An impedance labeling free electrochemical aptamer sensor based on tetrahedral DNA nanostructures for doxorubicin determination
- PMID: 38217713
- DOI: 10.1007/s00604-024-06176-9
An impedance labeling free electrochemical aptamer sensor based on tetrahedral DNA nanostructures for doxorubicin determination
Abstract
Based on the electrochemical impedance method, a marker-free biosensor with aptamer as a biometric element was developed for the determination of doxorubicin (DOX). By combining aptamer with rigid tetrahedral DNA nanostructures (TDNs) and fixing them on the surface of gold electrode (GE) as biometric elements, the density and directivity of surface nanoprobes improved, and DOX was captured with high sensitivity and specificity. DOX was captured by immobilized aptamers on the GE, which inhibited electron transfer between the GE and [Fe(CN)6]3-/4- in solution, resulting in a change in electrochemical impedance. When the DOX concentration was between 10.0 and 100.0 nM, the aptasensor showed a linear relationship with charge transfer resistance, the relative standard deviation (RSD) ranged from 3.6 to 5.9%, and the detection limit (LOD) was 3.0 nM. This technique offered a successful performance for the determination of the target analyte in serum samples with recovery in the range 97.0 to 99.6% and RSD ranged from 4.8 to 6.5%. This method displayed the advantages of fast response speed, good selectivity, and simple sensor structure and showed potential application in therapeutic drug monitoring.
Keywords: Aptamer; Doxorubicin; Electrochemical impedance spectroscopy; Sensor; Tetrahedral DNA nanostructure.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.
Similar articles
-
An aptamer-based biosensor for detection of doxorubicin by electrochemical impedance spectroscopy.Anal Bioanal Chem. 2018 Feb;410(5):1453-1462. doi: 10.1007/s00216-017-0786-8. Epub 2017 Dec 3. Anal Bioanal Chem. 2018. PMID: 29199352
-
DNA aptamers selection and characterization for development of label-free impedimetric aptasensor for neurotoxin anatoxin-a.Biosens Bioelectron. 2015 Jun 15;68:295-302. doi: 10.1016/j.bios.2015.01.002. Epub 2015 Jan 2. Biosens Bioelectron. 2015. PMID: 25594161
-
Label-free and sensitive faradic impedance aptasensor for the determination of lysozyme based on target-induced aptamer displacement.Biosens Bioelectron. 2009 Sep 15;25(1):94-9. doi: 10.1016/j.bios.2009.06.001. Epub 2009 Jun 10. Biosens Bioelectron. 2009. PMID: 19559590
-
An electrochemical aptasensor based on tetrahedral DNA nanostructures as a signal probe carrier platform for sensitive detection of patulin.Anal Chim Acta. 2020 Nov 22;1138:123-131. doi: 10.1016/j.aca.2020.09.025. Epub 2020 Sep 15. Anal Chim Acta. 2020. PMID: 33161973
-
Determination of soluble CD44 in serum by using a label-free aptamer based electrochemical impedance biosensor.Analyst. 2020 Jan 21;145(2):460-465. doi: 10.1039/c9an01764j. Epub 2019 Nov 29. Analyst. 2020. PMID: 31781712
Cited by
-
Electrochemical cytosensor utilizing tetrahedral DNA/bimetallic AuPd holothurian-shaped nanoparticles for ultrasensitive non-destructive detection of circulating tumor cells.Mikrochim Acta. 2024 May 6;191(6):298. doi: 10.1007/s00604-024-06378-1. Mikrochim Acta. 2024. PMID: 38709403
-
Nanoenzyme-based sensors for the detection of anti-tumor drugs.Mikrochim Acta. 2025 Jan 23;192(2):103. doi: 10.1007/s00604-024-06822-2. Mikrochim Acta. 2025. PMID: 39847110 Review.
References
-
- Zhang ZG, Yu XY, Wang Z, Wu P, Huang J (2015) Anthracyclines potentiate anti-tumor immunity: a new opportunity for chemoimmunotherapy. Cancer Lett 369(2):331–335. https://doi.org/10.1016/j.canlet.2015.10.002 - DOI - PubMed
-
- Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U (2021) Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother 139:111708. https://doi.org/10.1016/j.biopha.2021.111708 - DOI - PubMed
-
- Rivankar S (2014) An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther 10(4):853–858. https://doi.org/10.4103/0973-1482.139267 - DOI - PubMed
-
- Sheibani M, Azizi Y, Shayan M, Nezamoleslami S, Eslami F, Farjoo MH, Dehpour AR (2022) Doxorubicin-induced cardiotoxicity: an overview on pre-clinical therapeutic approaches. Cardiovasc Toxicol 22(4):292–310. https://doi.org/10.1007/s12012-022-09721-1 - DOI - PubMed
-
- Wu BB, Leung KT, Poon ENY (2022) Mitochondrial-targeted therapy for doxorubicin-induced cardiotoxicity. Int J Mol Sci 23(3):1912. https://doi.org/10.3390/ijms23031912 - DOI - PubMed - PMC